{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:26Z","timestamp":1772119586055,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10637-021-01105-6","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T18:21:01Z","timestamp":1616696461000},"page":"1411-1418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5174-8217","authenticated-orcid":false,"given":"Hui","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuezhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingcui","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,25]]},"reference":[{"issue":"1","key":"1105_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/1097-0142(195201)5:1<100::AID-CNCR2820050112>3.0.CO;2-K","volume":"5","author":"WM Christopherson","year":"1952","unstructured":"Christopherson WM, Foote FW, Stewart FW (1952) Alveolar soft part sarcomas; structurally characteristic tumors of uncertain histogenesis. Cancer 5(1):100\u2013111","journal-title":"Cancer"},{"key":"1105_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.biopha.2018.04.117","volume":"103","author":"MH Soheilifar","year":"2018","unstructured":"Soheilifar MH, Taheri RA, Zolfaghari Emameh R et al (2018) Molecular landscape in alveolar soft part sarcoma:implications for molecular targeted therapy. Biomed Pharmacother 103:889\u2013896","journal-title":"Biomed Pharmacother"},{"key":"1105_CR3","doi-asserted-by":"publisher","first-page":"428789","DOI":"10.1155\/2012\/428789","volume":"2012","author":"B Mitton","year":"2012","unstructured":"Mitton B, Federman N (2012) Alveolar soft part sarcomas: molecular pathogenesis and implications for novel targeted therapies. Sarcoma 2012:428789","journal-title":"Sarcoma"},{"issue":"2","key":"1105_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamaoncol.2018.4490","volume":"5","author":"L Paoluzzi","year":"2019","unstructured":"Paoluzzi L, Maki RG (2019) Diagnosis, prognosis, and treatment of alveolar soft part sarcoma: a review. JAMA Oncol 5(2):254\u2013260","journal-title":"JAMA Oncol"},{"issue":"3","key":"1105_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0761-8425(09)72591-4","volume":"26","author":"A Trabelsi","year":"2009","unstructured":"Trabelsi A, Ben Abdelkrim S, Taher Yacoubi M et al (2009) Sarcome alv\u00e9olaire primitif du poumon. Rev Mal Respir 26(3):329\u2013332","journal-title":"Rev Mal Respir"},{"key":"1105_CR6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13000-015-0399-5","volume":"10","author":"M Zhao","year":"2015","unstructured":"Zhao M, Rao Q, Wu C, Zhao Z, He X, Ru G (2015) Alveolar soft part sarcoma of lung: report of a unique case with emphasis on diagnostic utility of molecular genetic analysis for TFE3 gene rearrangement and immunohistochemistry for TFE3 antigen expression. Diagn Pathol 10:160","journal-title":"Diagn Pathol"},{"issue":"10","key":"1105_CR7","first-page":"771","volume":"41","author":"Y Tsutsumi","year":"1991","unstructured":"Tsutsumi Y, Deng YL (1991) Alveolar soft part sarcoma of the pulmonary vein. Acta Pathol Jpn 41(10):771\u2013777","journal-title":"Acta Pathol Jpn"},{"issue":"2","key":"1105_CR8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3346\/jkms.2007.22.2.369","volume":"22","author":"YD Kim","year":"2007","unstructured":"Kim YD, Lee CH, Lee MK et al (2007) Primary alveolar soft part sarcoma of the lung. J Korean Med Sci 22(2):369\u2013372","journal-title":"J Korean Med Sci"},{"issue":"5","key":"1105_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/jso.24183","volume":"113","author":"H Wang","year":"2016","unstructured":"Wang H, Jacobson A, Harmon DC et al (2016) Prognostic factors in alveolar soft part sarcoma: a SEER analysis. J Surg Oncol 113(5):581\u2013586","journal-title":"J Surg Oncol"},{"issue":"3","key":"1105_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5301\/tj.5000617","volume":"103","author":"P Jagodzi\u0144ska-Mucha","year":"2017","unstructured":"Jagodzi\u0144ska-Mucha P, \u015awitaj T, Kozak K et al (2017) Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. Tumori 103(3):231\u2013235","journal-title":"Tumori"},{"issue":"11","key":"1105_CR11","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1002\/pbc.24683","volume":"60","author":"D Orbach","year":"2013","unstructured":"Orbach D, Brennan B, Casanova M et al (2013) Paediatric and adolescent alveolar soft part sarcoma:a joint series from European cooperative groups. Pediatr Blood Cancer 60(11):1826\u20131832","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"1105_CR12","doi-asserted-by":"publisher","first-page":"E125","DOI":"10.1002\/hed.23648","volume":"36","author":"N Meng","year":"2014","unstructured":"Meng N, Zhang X, Liao A et al (2014) Management of recurrent alveolar soft-part sarcoma of the tongue after external beam radiotherapy with iodine-125 seed brachytherapy. Head Neck 36(12):E125\u2013E128","journal-title":"Head Neck"},{"issue":"12","key":"1105_CR13","doi-asserted-by":"publisher","first-page":"e27405","DOI":"10.1002\/pbc.27405","volume":"65","author":"M Sparber-Sauer","year":"2018","unstructured":"Sparber-Sauer M, Seitz G, Von Kalle T et al (2018) Alveolar soft-part sarcoma: primary metastatic disease and metastatic relapse occurring during long-term follow-up. Pediatr Blood Cancer 65(12):e27405","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1105_CR14","first-page":"690520","volume":"2013","author":"RF Falkensternge","year":"2013","unstructured":"Falkensternge RF, Kimmich M, Wohlleber M et al (2013) Lung metastasis of primary alveolar soft-part sarcoma occurring 20 years after initial treatment. Case Rep Oncol Med 2013(1):690520","journal-title":"Case Rep Oncol Med"},{"key":"1105_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/pbc.26942","volume":"65","author":"B Brennan","year":"2018","unstructured":"Brennan B, Zanetti I, Orbach D et al (2018) Alveolar soft part sarcoma in children and adolescents: the European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005). Pediatr Blood Cancer 65:4","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1105_CR16","doi-asserted-by":"publisher","first-page":"e26953","DOI":"10.1002\/pbc.26953","volume":"65","author":"RJ Flores","year":"2018","unstructured":"Flores RJ, Harrison DJ, Federman NC, Furman WL, Huh WW, Broaddus EG, Okcu MF, Venkatramani R (2018) Alveolar soft part sarcoma in children and young adults: a report of 69 cases. Pediatr Blood Cancer 65(5):e26953","journal-title":"Pediatr Blood Cancer"},{"issue":"21","key":"1105_CR17","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","volume":"24","author":"Y Chi","year":"2018","unstructured":"Chi Y, Fang Z, Hong X et al (2018) Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft tissue sarcoma. Clin Cancer Res 24(21):5233\u20135238","journal-title":"Clin Cancer Res"},{"key":"1105_CR18","doi-asserted-by":"publisher","first-page":"11503","DOI":"10.1200\/JCO.2018.36.15_suppl.11503","volume":"36","author":"Y Chi","year":"2018","unstructured":"Chi Y, Yao Y, Wang S et al (2018) Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo-controlled and multi-centered clinical trial. J Clin Oncol 36:11503","journal-title":"J Clin Oncol"},{"issue":"2","key":"1105_CR19","first-page":"4611","volume":"18","author":"HC Randrup","year":"2017","unstructured":"Randrup HC, Grimm D, Bauer J et al (2017) Effects and side effects of using sorafenib and sunitinib in the treatment of metastatic renal cell carcinoma. Inter J Mol Sci 18(2):4611\u20134625","journal-title":"Inter J Mol Sci"},{"issue":"6","key":"1105_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10637-016-0390-3","volume":"34","author":"T Li","year":"2016","unstructured":"Li T, Wang L, Wang H et al (2016) A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib. Investig New Drugs 34(6):1\u20136","journal-title":"Investig New Drugs"},{"key":"1105_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/TCRM.S84792","volume":"12","author":"LD Cranmer","year":"2016","unstructured":"Cranmer LD, Loggers ET, Pollack SM (2016) Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag 12:941\u2013955","journal-title":"Ther Clin Risk Manag"},{"key":"1105_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jchromb.2012.06.004","volume":"901","author":"M Minocha","year":"2012","unstructured":"Minocha M, Khurana V, Mitra AK (2012) Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC\/MS-MS). J Chromatogr B Analyt Technol Biomed Life Sci 901:85\u201392","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"1","key":"1105_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.2018-0464","volume":"24","author":"M Kim","year":"2019","unstructured":"Kim M, Kim TM, Keam B et al (2019) A phaseIItrial of pazopanib in patients with metastatic alveolar soft part sarcoma. Oncologist 24(1):20\u2013e29","journal-title":"Oncologist"},{"issue":"1","key":"1105_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","volume":"23","author":"S Stacchiotti","year":"2018","unstructured":"Stacchiotti S, Mir O, Le Cesne A et al (2018) Activity of pazopanib and trabectedin in advanced alveolar soft part sarcoma. Oncologist 23(1):62\u201370","journal-title":"Oncologist"},{"issue":"7","key":"1105_CR25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/s1470-2045(19)30215-3","volume":"20","author":"I Judson","year":"2019","unstructured":"Judson I, Morden JP, Kilburn L et al (2019) Cediranib in patients with alveolar soft part sarcoma (CASPS): a double blind, placebo controlled, randomised, phase 2 trial. Lancet Oncol 20(7):1023\u20131034. https:\/\/doi.org\/10.1016\/s1470-2045(19)30215-3","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"1105_CR26","doi-asserted-by":"publisher","first-page":"10540","DOI":"10.1200\/JCO.2018.36.15_suppl.10540","volume":"36","author":"J Glod","year":"2018","unstructured":"Glod J, Cohen JW, Widemann BC et al (2018) Cediranib phaseIIstudy in children with metastatic alveolar soft part sarcoma (ASPS). J Clin Oncol 36(15_suppl):10540","journal-title":"J Clin Oncol"},{"issue":"30","key":"1105_CR27","doi-asserted-by":"publisher","first-page":"50314","DOI":"10.18632\/oncotarget.18599","volume":"8","author":"Y Zhou","year":"2017","unstructured":"Zhou Y, Tang F, Wang Y et al (2017) Advanced alveolar soft part sarcoma responds to apatinib. Oncotarget 8(30):50314\u201350322","journal-title":"Oncotarget"},{"issue":"3","key":"1105_CR28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/annonc\/mdx774","volume":"29","author":"P Sch\u00f6ffski","year":"2018","unstructured":"Sch\u00f6ffski P, Wozniak A, Kasper B et al (2018) Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3:European Organization for Research and Treatment of Cancer (EORTC)phaseIItrial90101 \u2018CREATE\u2019. Ann Oncol 29(3):758\u2013765","journal-title":"Ann Oncol"},{"key":"1105_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12974\/2309-6160.2017.04.1","volume":"4","author":"AP Conley","year":"2017","unstructured":"Conley AP, Trinh VA, Zobniw CM et al (2017) Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma. J Global Oncol 4:1\u20136","journal-title":"J Global Oncol"},{"issue":"5","key":"1105_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41416-018-0100-3","volume":"119","author":"HN Mo","year":"2018","unstructured":"Mo HN, Huang J, Xu JC, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, Zhang H, Chi Y, Yang Q, Xu B (2018) Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer 119(5):538\u2013545","journal-title":"Br J Cancer"},{"issue":"11","key":"1105_CR31","doi-asserted-by":"publisher","first-page":"E2071","DOI":"10.3390\/molecules24112071","volume":"24","author":"K Guzik","year":"2019","unstructured":"Guzik K, Tomala M, Muszak D et al (2019) Development of the inhibitors that target the PD-1\/PD-L1 interaction-a brief look at progress on small molecules, peptides and macrocycles. Molecules 24(11):E2071","journal-title":"Molecules"},{"issue":"17","key":"1105_CR32","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1200\/JCO.18.02151","volume":"37","author":"J Nie","year":"2019","unstructured":"Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, Li X, Liu J, Ku W, Zhang Y, Chen M, An X, Shi L, Brock MV, Bai J, Han W (2019) Addition of low-dose decitabine to anti-PD-1 antibody camrelizumab in relapsed\/refractory classical Hodgkin lymphoma. J Clin Oncol 37(17):1479\u20131489","journal-title":"J Clin Oncol"},{"issue":"24","key":"1105_CR33","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.1158\/1078-0432.CCR-19-1680","volume":"25","author":"Y Song","year":"2019","unstructured":"Song Y, Wu J, Chen X, Lin T, Cao J, Liu Y, Zhao Y, Jin J, Huang H, Hu J, Luo J, Zhang L, Xue H, Zhang Q, Wang W, Chen C, Feng J, Zhu J (2019) A single- arm, multicenter, phase II study of camrelizumab in relapsed or refractory classical hodgkin lymphoma. Clin Cancer Res 25(24):7363\u20137369","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1105_CR34","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40265-019-01167-0","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ (2019) Camrelizumab: first global approval. Drugs 79(12):1355\u20131361","journal-title":"Drugs"},{"issue":"1","key":"1105_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.21037\/apm-20-2275","volume":"10","author":"Z Xu","year":"2021","unstructured":"Xu Z, Zhang Y, Yu YH (2021 Jan) Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: a case report. Ann Palliat Med 10(1):785\u2013792","journal-title":"Ann Palliat Med"},{"issue":"15 Suppl","key":"1105_CR36","first-page":"11013","volume":"37","author":"X Lu","year":"2019","unstructured":"Lu X, Wei G, Jie X et al (2019) Apatinib plus camrelizumab (SHR1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: a prospective, open label, phase II trial. J Clin Oncol 37(15 Suppl):11013","journal-title":"J Clin Oncol"},{"issue":"3","key":"1105_CR37","doi-asserted-by":"publisher","first-page":"E39","DOI":"10.1016\/j.ijrobp.2018.07.538","volume":"102","author":"Q Pang","year":"2018","unstructured":"Pang Q, Li X, Zhang W (2018) Safety and effect of radiation therapy combined with anti- PD- 1 antibody SHR- 1210 as firstline treatment on patients with intolerable concurrent chemoradiotherapy esophageal cancer: a phase 1b clinical trial. Int J Radiat Oncol Biol Phys 102(3):E39","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1105_CR38","first-page":"1206","volume":"24","author":"H Jing","year":"2018","unstructured":"Jing H, Binghe X, Hongnan M et al (2018) Safety, activity, and biomarkers of SHR-1210, an anti- PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res 24(6):1206\u20131304","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1105_CR39","doi-asserted-by":"publisher","first-page":"4031","DOI":"10.1200\/JCO.2019.37.15_suppl.4031","volume":"37","author":"L Shen","year":"2019","unstructured":"Shen L, Peng Z, Zhang YQ (2019) Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first-line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: updated results from a multicenter, open label phase II trial. J Clin Oncol 37(15):4031\u20134031","journal-title":"J Clin Oncol"},{"key":"1105_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/annonc\/mdy424.029","volume":"29","author":"SK Qin","year":"2018","unstructured":"Qin SK, Ren ZG, Meng ZQ et al (2018) A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann Oncol 29:719\u2013720","journal-title":"Ann Oncol"},{"issue":"2","key":"1105_CR41","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, Zhang G, Zhao C, Zhang Y, Chen C, Wang Y, Yi X, Hu Z, Zou J, Wang Q (2019) Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open- label, dose escalation and expansion study. Clin Cancer Res 25(2):515\u2013523","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1105_CR42","doi-asserted-by":"publisher","first-page":"e21017","DOI":"10.1200\/JCO.2018.36.15_suppl.e21017","volume":"36","author":"C Zhou","year":"2018","unstructured":"Zhou C, Gao G, Wu F (2018) A phase Ib study of SHR-1210 plus Apatinib for heavily previously treated advanced nonsquamous non- small cell lung cancer (NSCLC) patients [abstract no. e21017]. J Clin Oncol 36(15):e21017","journal-title":"J Clin Oncol"},{"issue":"10","key":"1105_CR43","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(18)30579-5","volume":"19","author":"DLW Kwong","year":"2018","unstructured":"Kwong DLW (2018) Camrelizumab for nasopharyngeal carcinoma: a new hope? Lancet Oncol 19(10):1266\u20131267","journal-title":"Lancet Oncol"},{"issue":"2","key":"1105_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"6","key":"1105_CR45","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","volume":"20","author":"BA Wilky","year":"2019","unstructured":"Wilky BA, Trucco MM, Subhawong TK et al (2019) Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft part sarcoma: a single centre, single arm, phase 2 trial. Lancet Oncol 20(6):837\u2013848","journal-title":"Lancet Oncol"},{"issue":"9","key":"1105_CR46","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1158\/2326-6066.CIR-18-0037","volume":"6","author":"J Lewin","year":"2018","unstructured":"Lewin J, Davidson S, Anderson ND et al (2018) Response to immune checkpoint inhibition in two patients with alveolar softpart sarcoma. Cancer Immunol Res 6(9):1001\u20131007","journal-title":"Cancer Immunol Res"},{"issue":"15_suppl","key":"1105_CR47","doi-asserted-by":"publisher","first-page":"11572","DOI":"10.1200\/JCO.2018.36.15_suppl.11572","volume":"36","author":"S Yang","year":"2018","unstructured":"Yang S, Yang J, Han X et al (2018) Effect of JS001, a monoclonal antibody targeting programed death-1(PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma:results from a phase 1 trial. J Clin Oncol 36(15_suppl):11572","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01105-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01105-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01105-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:08:35Z","timestamp":1678493315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01105-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,25]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01105-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-190035\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,25]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The case report comply with the current laws of the country in which he was performed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We obtained informed consent from the patient in this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publish"}},{"value":"Hui Su declares no conflict of interest, Chao Yu declares no conflict of interest, Xuezhen Ma declares no conflict of interest, Qingcui Song declares no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}